Clostridium difficile diagnostika. Paul Naaber

Similar documents
Objectives Clostridium difficile Infections, So Many Tests, Which One to Choose?

Clostridium difficile Testing Algorithms Using Glutamate Dehydrogenase Antigen and C.

DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015

Laboratory diagnosis of Clostridium difficile infection

Rapid and Sensitive Loop-Mediated Isothermal Amplification (LAMP) Test for. Gold Standard

on November 8, 2018 by guest

EVALUATION OF THE COBAS LIAT (ROCHE ) AND THE LIAISON MDX (DIASORIN )

Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)

"QUIK CHEK"[tw])) NOT ((therapy[ti] OR treatment[ti] OR treat*[ti]) NOT (diagnosis[ti] OR

Jen KOK*, Qinning WANG, Lee C THOMAS, Gwendolyn L GILBERT. Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of

JMSCR Vol 05 Issue 07 Page July 2017

Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections

New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility

Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection

C. DIFF QUIK CHEK COMPLETE. Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE NEXT PAGE

The Bristol Stool Scale and Its Relationship to Clostridium difficile Infection

Clostridium difficile: An Overview

Evaluation of BD GeneOhm CDiff PCR Assay for Diagnosis of Toxigenic Clostridium difficile Infection

! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery

The disease formerly called Clostridium difficile associated

Clostridium difficile infection: New Zealand perspective

S (15) DOI: doi: /j.diagmicrobio Reference: DMB 13832

SC P. on POOP. Susan E. Sharp, Ph.D., DABMM Director of Microbiology Portland, OR

INFECTION WITH TOXIN A-NEGATIVE, TOXIN B-NEGATIVE, BINARY TOXIN- POSITIVE CLOSTRIDIUM DIFFICILE IN A YOUNG PATIENT WITH ULCERATIVE COLITIS

Infektsioon artroskoopia järgselt. Madis Rahu ETOS tüsistuste seminar Eivere

Protocol for the Scottish Surveillance Programme for Clostridium difficile infection.

A Pharmacist Perspective

Clostridium difficile Infection (CDI) Guideline Update:

EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE

DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE

Comprehensive evaluation of chemiluminescent immunoassays for the laboratory diagnosis of Clostridium difficile infection

Clostridium difficile Infection (CDI) Management Guideline

Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital

Clostridium difficile Asymptomatic Carriers The Hidden Part of the Iceberg?

Session VIII: Clostridium difficile: Epidemiology

Clostridium difficile associated diarrhoea HIV and CD4 count in Malawi

C. difficile infection

ESCMID Online Lecture Library. by author

COMPARISON OF THE PREVALENCE AND GENOTYPIC CHARACTERISTICS OF CLOSTRIDIUM DIFFICILE IN A CLOSED AND INTEGRATED HUMAN AND SWINE POPULATION IN TEXAS

3/23/2012. Impact of Laboratory Testing on Detection and Treatment of Healthcare Associated Infection: The Case of CDI

Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection

Pre-Assessment Review: Microbiology, Part 2: Virology. Dr. David Hillyard

11/14/10. A Modern Plague: Clostridium difficile and Inflammatory Bowel Disease

Historical Perspective

500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired

ESCMID Online Lecture Library. by author

L. Clifford McDonald, MD. Senior Advisor for Science and Integrity September 16, 2015

C. Difficile Testing Protocol

THE NEW ZEALAND MEDICAL JOURNAL

Clostridium difficile: Can you smell the new updates?

Questions and answers about the laboratory diagnosis of Clostridium difficile infection (CDI)

Clostridium difficile 027, A Southern Hemisphere Perspective Dr. David Hammer, Medlab South, New Zealand A Webber Training Teleclass

Mitteinvasiivne ventilatsioon kiirabi ja EMO praktikas, ehk morfiinivaba kopsuturse ravi

Molecular Testing in Infectious Diseases. Objectives 5/9/2014. Implementing Molecular Testing for Infectious Diseases Diagnosis

Indeterminate tcdb using a Clostridium difficile PCR assay: a retrospective cohort study

Original Article. Infection Control & Hospital Epidemiology (2019), 1 5 doi: /ice

Can a toxin gene NAAT be used to predict toxin EIA and the severity of Clostridium difficile infection?

What s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington

Supplementary Online Content

Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of toxigenic Clostridium difficile in fecal specimens

Los Angeles County Department of Public Health: Your Partner in CDI Prevention

Incidence, case fatality and genotypes causing Clostridium difficile infections, Finland, 2008*

Äge keskkõrvapõletik - kas ravida või mitte. Eda Tamm SA TÜK Lastekliinik Türi 2012

This is a repository copy of Clostridium difficile infection: advances in epidemiology, diagnosis and transmission.

Sc. boulardii- milles peitub tema tugevus. Merli Špitsmeister Biokeemia ja biotehnoloogia MSc

Clostridium difficile Infection: Diagnosis and Management

Clostridium difficile infection in patients with inflammatory bowel disease

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Surveillance and outbreak report

CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates

The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review

Epstein-Barri ja tsütomegaloviiruse serodiagnostika. Maire Tehvre

Modern approach to Clostridium Difficile Infection

HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS

Clostridium difficile infection surveillance: Applying the case definition

Clostridium difficile Infection (CDI)

SESSION VII CLOSTRIDIUM DIFFICILE: EPIDEMIOLOGY

REVIEW. Ó 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

ICU-Onset Clostridium difficile Infection in a University Hospital in China: A Prospective Cohort Study

Comparison of Clinical Features Between Inpatient and Outpatient Cases of Clostridium difficile Infection

Persistence of Skin Contamination and Environmental Shedding of Clostridium difficile during and after Treatment of C. difficile Infection

IHI Expedition Reducing Clostridium difficile Infections Session 2: Rapid Detection and Isolation

Clostridium difficile Update

MONDAY, JANUARY 29, 2007

C. difficile Infection: How it all comes out

Clostridium difficile infections Crappy Options

Clostridium difficile: a healthcare associated infection of unknown significance in adults in sub-saharan Africa.

Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine

Reference assays for Clostridium difficile infection: one or two gold standards?

Rapid-VIDITEST C. difficile Ag (GDH) Card/Blister

In vivo pathogenicity and sporulation patterns of Clostridium difficile. Natalia Blanco Herrera

APIC NHSN Webinar. May 16, National Center for Emerging and Zoonotic Infectious Diseases

Clostridium difficile infection (CDI)- what s new in diagnosis and treatment; target of antibiotic stewardship

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

Updated Clostridium difficile Treatment Guidelines

Antifibrinolüütikumid-kellele ja. Kristjan Kalling, Põhja-Eesti Regionaalhaigla

Emergence of Clostridium difficile-associated disease in Canada, the United States of America and Europe.

Puukborrelioos Saaremaal

TITLE OF PRESENTATION

Transcription:

Clostridium difficile diagnostika Paul Naaber Paul Naaber 08.12.2011

Sissejuhatus Grampositiivne anaeroob Moodustab eoseid Virulentsusfaktorid Toksiin A ja B olulised haiguse tekkes binary toxin tähtsus ebaselge Haigus asümptomaatiline seedetrakti kolonisatsioon: 3-5(-50?) % tervetesl täiskasvanutel haiglaväliselt sage (ca 50%) alla 2 aastastel lastel 7-50% hospitaliseeritutest antibiootikumraviga seotud kõhulahtisus (AAD) pseudomembranoosne koliit (PMC) 2

3 S. M. Poutanen et al. CMAJ (2004) 171: 51-58

Probleemi olulisus CDI juhu hind (13 uuringut, EU, USA, Kanada) esmane haigusjuht 2 871-8 570 USD korduv CDI 13 655 18 067 CD haiglavälise CD infektsiooni osatähtsus suureneb UK: CDAD diagnoosimine perearstide poolt suurenud 1-lt 22 juhuni /100,000 suureneb haigestumus ja komplitseeritud juhtude arv Kanada 1991-2003: sagedus 36-t 156 juhuni 100 000; komplitseeritud juhtude arv 7-lt 18%-ni 4

Diagnostika meetodid: sissejuhatus CD produktide määramine Toksiin A ja/või B EIA - A+B» Immuunkromogeensed kiirtestid, well-type ELISA rakukultuur -toksiin B GDH (glutamaat dehüdrogenaas) kultiveerimine CCFA, Brazier s CCEYA, CDMN, chromid CD geenide määramine kommertsiaalsed real-time PCR GeneOhm (Beckton Dickinson): tcdb Xpert (Cephid): tcdb; cdta/cdtb; tcdc-deletion Prodesse ProGastro Cd: tcdb (Meridian Illumigene, Loop-Mediated Isothermal Amplification: tcda) in-house 5

Toxin A/B EIA (membrane) Toxin A/B EIA (well-type) GDH EIA (membrane) GDH EIA (welltype) Sensitivity % Range (Mean) 31-96 (72)# 32-77 (52)* 57-99 (82)# 48-79 (66)* Real-time PCR 87-100# 84-86* Specificity% Range (Mean) 65-100 (98)# 84-100 (98)* 87-100 (97)# 97-100 (98)* Eelised Sobib üksikuteks testideks Kiire, spetsiifiline, parem korrelatsioon kliinilise haigusega 80-97 (90)# 75-100 (90)# Sobib üksikuteks testideks 91-96 (93)# 89-100 (89)# 94-100# 97-98* kiire; kõrge NPV (95-100); sobilik skriininguks Tundlik ja spetsiifiline Puudused Madalam tundlikkus kui külvil; ei saa mikroobi tüve Madalam spetsiifilisus, positiivsed juhud tuleks kinnitada Kallim?; ei saa mikroobi tüve Külv ja tüve toksilisuse test Tundlik ja spetsiifiline; tüvi edasisteks uuringuteks Töö ja ajamahukas, vaja anaeroobse külvi süsteeme Toksiini määramine rakukultuuril Tundlik ja spetsiifiline Töö ja ajamahukas; vaja rakukultuure; ei saa mikroobi tüve # compared with cell culture cytotoxity assay; * compared with toxigenic culture 6

(Toksiini) testi tundlikkus sõltub tüvest 7

Diagnostika meetodid: soovitused külv (koos tox testiga kultuurist) +/- otsene tox test selektiivne sööde +/- alkohol sokk + tox test CD tüvest tox A+B EIA (rakukultuur) PCR (+/- külv) real-time PCR külv (epidemioloogiline vms vajadus) 2 astmelised algoritmid skriining-test positiivsete juhtude kinnitamine 8

CD diagnostika algoritm (näidis) Skriiningtest GDH GDH neg Vasta: CD neg GDH pos Kinnitav test: toksiin (+ külv) (Toks pos: vasta CD pos) Toksiin ja külv neg Vasta: CD neg Toksiin pos (külv pos v. neg) Vasta: CD pos Toksiin neg ja külv pos Määra toksiin CD tüvel Toksiin pos tüvi Vasta: CD pos Toksiin neg tüvi Vasta: CD neg 9

proovide säilitamine Proovivõtt C. difficile vegetatiivsed rakud ja eosed - külviks temp suurt ei mõjuta, hulgad stabiilsed päevi (nädalaid) CD toksiinid EIA testiks +4 C stabiilne päevi (nädalaid) -20 C ja (mitmed) külmutus/sulatus tsüklid vähendavad tundlikkust oluliselt 10

Näidustused EI ole näidustatud asümptomaatiliste patsientide skriining reeglina EI ravi kontrolli uuringud - reeglina EI (kuni 30% jäävad CD pos) mitte-vedela väljaheite uuringud - EI ON näidustatud kõik hospitaliseeritud patsiendid (>3d) kellel kõhulahtisus (sõltumata uuringu tellimisest)? haiglavälised patsiendi AB kõhulahtisusega? Epidemioloogilistel näidustustel AB tundlikkuse testimine tüpiseerimine 11

Infektsioon v kolonisatsioon? mida tundlikumad testid, seda enam avastame ka kolonisatsiooni kolonisatsioon + kõhulahtisus muust mehhanismist (patogeenist) 44 99% of AAD pole CD põhjustatud 7-50% haiglapatsientidest on CD-ga koloniseeritud seega, CD kolonisatsioon ja non-cd kõhulahtisus on võimalik kokkusattumus kas lab saab neid juhtumeid eristada? muud põletiku markerid: PMN; lactoferrin test pole spetsiifilised ega tundlikkud toksiini esinemine sooles viitab tõelisele infektsioonile? pole kindel marker 12

mild CDI vs. severe CDI: fecal toxin level 13